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Abstract
Background: Iatrogenic skin and soft tissue infections by rapidly growing mycobacteria are described with
increasing frequency, especially among immunocompromised patients.
Case presentation: Here, we present an immunocompetent patient with extensive Mycobacterium fortuitum skin
and soft tissue infections after subcutaneous injections to relieve joint pains by a Vietnamese traditional medicine
practitioner. Moreover, we present dilemmas faced in less resourceful settings, influencing patient management.
Conclusion: This case illustrates the pathogenic potential of rapid growing mycobacteria in medical or
non-medical skin penetrating procedures, their world-wide distribution and demonstrates the dilemmas faced in
settings with fewer resources.
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Background
Mycobacterium fortuitum is a member of the group of
non-pigmented Rapidly Growing Mycobacteria (RGM),
and is found ubiquitously in nature (soil, dust, and in
tap water in biofilms), over a wide geographical area. In-
fections with non-tuberculous mycobacteria have been
described increasingly, especially in immunocompromised
patients and as iatrogenic infections in immunocompetent
patients, causing a variety of local and disseminated dis-
ease. RGM in particular can cause local skin and soft tis-
sue infections (SSTI) and have also been described in
outbreak and pseudo-outbreak settings involving infec-
tions after surgery or other invasive procedures [1-3].
Here, we describe a case from the Hospital of Tropical
Diseases in Ho Chi Minh City, Vietnam of M. fortuitum
infection of the skin and soft tissues covering several
joints after injection of traditional Vietnamese medicine
to relieve joint pain. We discuss the diagnostic process
and treatment for this patient in a setting with fewer
resources.
Case presentation
An immunocompetent, 61-year old female patient from
Ho Chi Minh City, Vietnam, was admitted to the Hos-
pital for Tropical Diseases with multiple painful fluctuat-
ing and non-fluctuating masses on both hands and feet
(see Figure 1) and on her back. She was also subfebrile
(37.8°C). Her previous history was uneventful except for
mild hypertension and a hysterectomy because of a benign
tumour. For the past 2 years she experienced numbness in
both hands and feet, which was the reason for consulting
a Vietnamese traditional medicine practitioner 15 days
prior to admission. For three consecutive days, the patient
received an oral preparation, as well as multiple subcuta-
neous injections (at the metacarpophalangeal and meta-
tarsophalangeal joints of the hands and feet, and at the
shoulder and hip joints) with a red substance, both of un-
known composition. Five days post-injection, the injection
sites became erythematous, painful, and swollen. She de-
veloped a fever and was treated at a local clinic with
* Correspondence: rvandoorn@oucru.org
1The Hospital for Tropical Diseases, Ho Chi Minh, Vietnam
2Oxford University Clinical Research Unit, Wellcome Trust Major Overseas
Programme, 764 Vo Van Kiet, Quan 5, Ho Chi Minh, Vietnam
Full list of author information is available at the end of the article
© 2014 Lan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Lan et al. BMC Infectious Diseases 2014, 14:550
http://www.biomedcentral.com/1471-2334/14/550
unknown (antimicrobial) drugs without clinical improve-
ment, after which she was admitted to our hospital.
Laboratory findings showed: procalcitonin 0.083 ng/ml
(reference range <0.05 ng/ml), leucocytes 14.8 • 103/μl
(6-10 • 103/μl), neutrophiles 81.2% (reference range: 49-
65.5%). Blood cultures (BactAlert; bioMérieux, France)
were taken and empiric antimicrobial therapy was started
with intravenous (i.v.) oxacilline to cover Staphylococcus
aureus and group A beta-haemolytic streptococci.
A pulmonary X-ray, and X-ray imaging of hands and
feet were unremarkable, and incision and drainage of the
abscesses followed. Gram stains of the collected fluids
showed slender beaded and fragmentally stained Gram
positive rods, suggestive of mycobacteria. This was subse-
quently confirmed by Ziehl-Neelsen staining (see Figure 1).
Because of reported sensitivity loss and the presence of
nodules, leprosy was ruled out by investigation of ear lobe
skin slits.
Based on microscopy results, a preliminary diagnosis of
multiple mycobacterial skin and soft tissue infections (SSTI)
with rapidly growing mycobacteria was made, and treat-
ment was initiated with oral clarithromycine (500 mg/b.i.d.)
and intramuscular (i.m.) amikacin (500 mg/t.i.d.).
Purulent fluid was cultured on standard culture media
(blood agar and McConkey agar) for three days and
yielded grey wrinkled colonies on blood agar (no growth
on McConkey agar) (see Figure 1), morphologically sus-
pect of Mycobacterium spp. This was confirmed by Gram
and ZN staining and the isolate was later genotyped as
Mycobacterium fortuitum by 16S DNA PCR and sequen-
cing analysis.
Initial drug susceptibility testing (DST) by disk diffu-
sion on Müller-Hinton agar showed the strain to be re-
sistant to fluoroquinolones (ciprofloxacin, levofloxacin),
azithromycin and tobramycin, but susceptible to amika-
cin, imipenem and amoxicillin-clavulanic acid. Clinical
improvement during the 120-day admission was variable
and slow, with subfebrile temperatures (38°C) last moni-
tored on day 14, and the appearance of new fluctuating
lesions on days 23 (hands/feet), 29 (hands/feet), 32 (right
Figure 1 Top, left to right: pretreatment pictures of hands and feet at day 4 and during treatment at day 67, respectively. Bottom, left
to right: two pictures of a Ziehl-Neelsen stain (1000X) of aspirated pus from the abscess on dorsal side of the patient’s right hand (acid-fast bacilli
indicated with arrowheads), and a blood agar plate of aspirated pus showing non-pigmented dry colonies of Mycobacterium fortuitum after 4 days
incubation (with two contaminating yellow colonies in the middle and bottom of the plate).
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shoulder and hip), and 72 (shoulder), which were incised
and drained. M. fortuitum was isolated again from the
day-23 and day-29 samples, whilst microscopy and cul-
ture remained negative thereafter. Papules and blisters
emerged at the sites of formerly drained sites on the
hands/feet on day 72 and 80, and healed 5 days later;
microbiological investigations were negative. From day
90 onwards, all lesions healed (see Figure 1), and no new
skin and soft tissue abnormalities were observed.
Antimicrobial therapy was adjusted several times dur-
ing admission based on repeated DST results and fi-
nancial incentives. Empiric treatment was started with
amikacin (i.m. 500 mg/t.i.d.) and oral clarithromycin
(500 mg/b.i.d.). This was later changed to amikacin (i.m.
500 mg/t.i.d.), doxycycline (100 mg/b.i.d.) and trimetho-
prim-sulfamethoxazole (co-trimoxazole, 960 mg/b.i.d.),
after culture results and pending additional DST. Imipe-
nem, to which the isolate was susceptible but which the
patient could not afford, was not given at this time.
Once resistance to tetracyclines and co-trimoxazole were
reported and amikacin had been administered for 14 days,
therapy was adjusted to imipenem monotherapy i.v.
500 mg/t.i.d, and later (day 50) to imipenem 1 gram/q.i.d,
based on international guidelines. Imipenem therapy was
funded by the hospital. The patient was discharged on day
120, at which point imipenem was changed to oral
amoxicillin-clavulanic acid (500/125 mg/t.i.d.), and follow-
up visits transpired for 8 months. Antimicrobial treatment
was stopped 4 months after discharge, while clinical
improvement was observed 1 month after discharge
(Table 1).
Our patient was not immunocompromised, as were
21/29 cases described by Lee et al., yet had extensive le-
sions which were spreading, even during therapy [4].
The number and location of lesions on initial presen-
tation correlated with the received subcutaneous in-
jections. Guevara-Patinos et al. describe M. fortuitum
infection with multiple skin lesions after acupuncture.
This was treated with doxycycline and ciprofloxacin for
three months which led to full recovery [5]. Pai et al.
describe a case of recurrent subcutaneous abscesses of
unknown aetiology that did not respond to empiric anti-
biotic treatment and later was diagnosed as a M. fortui-
tum SSTI [6]. Because of side effects, this patient was
eventually successfully treated with surgical excisions.
The development of several new nodules/abscesses dur-
ing antimicrobial therapy was worrisome in our case,
as this could be indicative of failure of antimicrobial
Table 1 Clinical course and therapy
Day History Diagnostics Treatment
-15 Received injections
-10 Start of symptoms
Treatment at local clinic Unknown
0 Admission, drainage of lesions
1 Acid-fast bacilli in ZN slide Amikacin IV, clarithromycin





15 Imipenem IV, tid
23 New lesions on hands/feet Acid-fast bacilli in ZN slide
29 New lesions on hands/feet Acid-fast bacilli in ZN slide
32 New lesions on shoulder/hip ZN/culture negative
50 Imipenem IV, qid
72 New lesions on shoulder ZN/culture negative
Papules on hands/feet
Papules on hands/feet
90 All lesions healed
110
120 Discharge Amoxicillin-clavulanic acid
Stop after 4 months
Legends: ZN: Ziehl Neelsen; DST: Drug Susceptibility Test; IV: intravenous; tid: ter in die (three time a day); qid: quater in die (four times a day).
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therapy due to misinterpretation of the susceptibility
results, resistance development or dissemination in an
ongoing extensive infection [7,8]. The gold standard
for susceptibility testing of RGM is the broth dilution
method as described by the CLSI [8]. In our setting,
broth dilution was unavailable. For imipenem an E-test
was performed, for ciprofloxacin, levofloxacin, tobramycin,
azithromycin, co-trimoxazole, amikacin and amoxicillin-
clavulanic acid disk diffusion was performed on Müller-
Hinton agar.
Our patient’s treatment regimen was altered on many
occasions, but overall, 105 days of imipenem monother-
apy was prescribed, in addition to the 14 days of amika-
cin therapy and 4 months of amoxicillin-clavulanic acid,
for which the isolate was sensitive according to disk dif-
fusion. After discharge and an 8 months follow-up
period, she remained free of symptoms.
Conclusion
In conclusion, M. fortuitum and other RGM are not very
pathogenic, but can cause infections after direct inocula-
tion into sterile sites, e.g. trauma with skin damage, use
of contaminated surgical instruments or fluid for injec-
tion or after use of contaminated tap water during inva-
sive procedures [7]. Infections with M. fortuitum appear
to occur in younger patients who are generally not im-
munocompromised, and manifest more often after surgi-
cal procedures [9]. M. fortuitum is more sensitive to
antibiotics than the related M. abscessus or M. chelonae
and infections have a better recovery rate [10]. In our
case, the isolate was relatively resistant by disk diffusion
tests and only susceptible to amikacin, imipenem and
amoxicillin-clavulanic acid. The patient clinically recov-
ered after more than 12 weeks of antimicrobial therapy,
which was continued for a total of 8 months. This case
illustrates the pathogenic potential of RGM in medical
or non-medical skin penetrating procedures and their
world-wide distribution. Additional dilemmas faced in this
setting with less resources were the limited availability of
(biochemical) typing and susceptibility testing methods, of
required antibiotics and of insurance coverage.
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